Editas Medicine Files 8-K with Material Agreement

TL;DR

Editas Medicine just filed an 8-K detailing a new material agreement and financial obligations.

AI Summary

On October 3, 2024, Editas Medicine, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also issued a Regulation FD disclosure and filed financial statements and exhibits as part of this 8-K filing.

Why It Matters

This filing indicates a significant new agreement for Editas Medicine, which could impact its financial obligations and future operations.

Risk Assessment

Risk Level: medium — Material definitive agreements and financial obligations can introduce new risks or alter existing ones for a company.

Key Players & Entities

• Editas Medicine, Inc. (company) — Registrant
• October 3, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
• $57.0 million — ment by the Purchaser to the Company of $57.0 million in exchange for the acquisition by the
• $5.0 million — icense Agreement, which fees range from $5.0 million to $40.0 million per year (inclusive of
• $40.0 million — , which fees range from $5.0 million to $40.0 million per year (inclusive of certain sales-ba
• $50.0 million — and a mid-double-digit percentage of a $50.0 million contingent upfront payment that the Com

Filing Documents

• edit-20241003.htm (8-K) — 35KB
• projecteclipse-pressreleas.htm (EX-99) — 13KB
• image_0.jpg (GRAPHIC) — 10KB
• 0001650664-24-000111.txt ( ) — 191KB
• edit-20241003.xsd (EX-101.SCH) — 2KB
• edit-20241003_lab.xml (EX-101.LAB) — 21KB
• edit-20241003_pre.xml (EX-101.PRE) — 12KB
• edit-20241003_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 3, 2024, Editas Medicine, Inc. (the "Company") entered into a purchase and sale agreement (the "Purchase and Sale Agreement") with a wholly-owned subsidiary of DRI Healthcare Trust (the "Purchaser") providing for an upfront cash payment by the Purchaser to the Company of $57.0 million in exchange for the acquisition by the Purchaser of certain future license fees and other payments (the "Purchased Receivables") owed to the Company by Vertex Pharmaceuticals Incorporated ("Vertex") under the terms of a license agreement (the "License Agreement") between the Company and Vertex dated as of December 12, 2023. Under the License Agreement, the Company granted Vertex a non-exclusive license for the Company's Cas9 gene-editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and transfusion-dependent beta thalassemia, including Vertex's CASGEVY (exagamglogene autotemcel). Under the Purchase and Sale Agreement, the Purchaser is purchasing up to 100% of certain future fixed and sales-based annual license fees owed to the Company under the License Agreement, which fees range from $5.0 million to $40.0 million per year (inclusive of certain sales-based annual license fees that may become due), and a mid-double-digit percentage of a $50.0 million contingent upfront payment that the Company may receive under the License Agreement, in each case after subtracting amounts owing by the Company to its licensors, The Broad Institute, Inc. and the President and Fellows of Harvard College. The Company has retained certain rights to its portions of certain sales-based annual license fees and the contingent upfront payment that may become due under the License Agreement, and the amounts that correspond to its licensor obligations. The Purchaser has no recourse to the Company's assets other than the Purchased Receivables and is entitled to payment for the Purchased

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 3, 2024, the Company issued a press release announcing the entry into the Purchase and Sale Agreement, a copy of which press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 and Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on October 3, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed. This Report contains forward-looking statements addressing the Purchase and Sale Agreement and the transactions contemplated in the Purchase and Sale Agreement and other statements about future expectations, prospects, estimates and other matters that are dependent upon future events or developments. All statements, other than those of historical fact, contained in this Report are forward-looking statements, including statements regarding the Company's expectations with respect to the Purchase Receivables and the potential payments to the Company by Vertex. Forward-looking statements may be identified by the words "look forward", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. The Company's actual results could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to payments actually received from Vertex pursuant to the License Agreement; and the factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K as well as any updates to these risk factors filed from time to time in the Company's other filings with the Securities and Exchange Commission.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: October 3, 2024 By: /s/ Erick Lucera Erick Lucera Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR